On August 5, 2025, Elicio Therapeutics announced that their Phase 2 AMPLIFY-7P study for pancreatic cancer will proceed to final analysis without changes, as recommended by the Independent Data Monitoring Committee. This positive development supports the ongoing research into their treatment for mutant KRAS-driven pancreatic ductal adenocarcinoma.